Jason Joel Schwartz
Physician in Salt Lake City, UT

License number
Utah 5950069-8905
Issued Date
Sep 2, 2005
Expiration Date
Jan 31, 2012
Category
Physician
Type
Physician/Surgeon CS (Schedule 2-5)
Address
Address
Salt Lake City, UT
Education
UNIVERSITY OF ILLINOIS COLLEGE OF MEDICINE

Professional information

Jason J Schwartz Photo 1

Dr. Jason J Schwartz - MD (Doctor of Medicine)

Specialties:
General Surgery
Procedures:
Dressing and/or Debridement of Wound, Infection, or Burn (incl. Negative Pressure Wound Therapy), Incisional/Ventral Hernia Repair, Open, Pancreatectomy (incl. Pancreas Transplant & Whipple Procedure), Peripheral Artery Catheterization, Port Placements or Replacements, Renal Transplant and Nephrectomy
Conditions:
Hyperparathyroidism, Incisional Hernia, Intestinal Obstruction, Liver Cancer, Peripheral Vascular Disease (PAD, PVD)
Certifications:
General Surgery, 2004
Awards:
Healthgrades Honor Roll
Languages:
English
Hospitals:
University Hospital
30 N 1900 E, Salt Lake City 84132
University of Utah Health Care
50 North Medical Dr, Salt Lake City 84132
University Hospital
30 N 1900 E, Salt Lake City 84132
University of Utah Health Care
50 North Medical Dr, Salt Lake City 84132
Education:
Medical School
University Of Illinois College Of Medicine Chicago
Graduated: 1996
University Of Tx Sw Med Center
Graduated: 1997
Graduated: 2002
Mayo Clinic
Graduated: 2005
University Of Tx
Graduated: 2001


Jason Schwartz Photo 2

Account Management At Ebay

Position:
Account Management at eBay
Location:
Greater Salt Lake City Area
Industry:
Internet
Work:
eBay - Account Management


Jason Schwartz Photo 3

Use Of Angiogenesis Antagonists In Conditions Of Abnormal Venous Proliferation

US Patent:
2011000, Jan 6, 2011
Filed:
Nov 10, 2008
Appl. No.:
12/741979
Inventors:
Jason Joel Schwartz - Salt lake City UT, US
Thomas P. Kennedy - Charlotte NC, US
International Classification:
A61K 31/27, A61K 31/315, A61P 1/16
US Classification:
514491, 514476
Abstract:
The present application describes therapy with angiogenesis antagonists such as anti-VEGF antibodies. In particular, the application describes the use of such angiogenesis antagonists to treat end-stage liver disease and end-stage liver disease complications. The present application also describes the use of such angiogenesis antagonists to treat disorders of altered venous proliferation such hemorrhoids and varicose veins.